Wellbutrin Does Not Help with Cognition in Dementia
Do not use Wellbutrin (bupropion) for cognitive improvement in dementia—the highest quality randomized controlled trial shows it provides no benefit for cognition or apathy, and it is not FDA-approved for this indication.
Evidence Against Bupropion for Dementia
The most definitive evidence comes from a 2020 multicenter, double-blind, placebo-controlled trial specifically testing bupropion in Alzheimer's dementia 1. This study enrolled 108 patients with mild-to-moderate Alzheimer's disease and found:
- No improvement in cognition: The mean change in cognitive scores between bupropion and placebo groups was not statistically significant (P = .86)
- No improvement in apathy: The primary outcome (Apathy Evaluation Scale) showed no significant difference (P = .11)
- Worse neuropsychiatric symptoms: Patients on bupropion actually had significantly worse total neuropsychiatric symptoms compared to placebo (P = .003)
- Worse quality of life: Health-related quality of life declined more in the bupropion group (P = .02)
FDA Labeling and Approved Treatments
The FDA label for Wellbutrin explicitly warns that it "may impair their ability to perform tasks requiring judgment or motor and cognitive skills" 2. Bupropion is approved only for depression and smoking cessation—not for dementia or cognitive enhancement.
The only FDA-approved medications for dementia cognition are cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine 3, 4. Even these show only "statistically significant but clinically marginal improvement" with small effect sizes (1-3 points on ADAS-cog, below the 4-point threshold for clinical significance) 3.
Guideline Recommendations
Current clinical practice guidelines from the American College of Physicians and American Academy of Family Physicians recommend only cholinesterase inhibitors and memantine for dementia treatment 4. These guidelines explicitly state:
- Base treatment decisions on individualized assessment with these approved agents
- Choose based on tolerability, adverse effects, ease of use, and cost
- No other pharmacologic agents have sufficient evidence 4
The 2020 Canadian Consensus Conference reinforces that cognitive enhancers should be discontinued in patients where they provide no benefit, and specifically states they should be deprescribed for mild cognitive impairment 5.
Conflicting Observational Data
While some observational studies suggest associations between bupropion and better cognitive performance 6, 7, these are confounded by indication—people taking bupropion for depression may have different baseline characteristics. The 2026 UK Biobank study actually found that baseline antidepressant use (including bupropion) was associated with higher dementia risk (HR 1.47), worse cognitive performance, and adverse brain structural changes 8.
Recent preclinical research in mouse models shows potential mechanisms for catecholamine effects on amyloid 9, and a 2025 meta-analysis suggests dopaminergic drugs (particularly MAO-B inhibitors, not bupropion) may have modest cognitive benefits 10. However, these do not translate to clinical efficacy in the definitive human trial 1.
Clinical Bottom Line
Use FDA-approved cholinesterase inhibitors or memantine if pharmacologic treatment is warranted for dementia cognition, recognizing even these have only marginal clinical benefit. Bupropion failed its primary trial, worsened neuropsychiatric symptoms, and carries seizure risk—particularly concerning in elderly patients with dementia who may have increased seizure susceptibility 2.
If a patient with dementia has comorbid depression requiring treatment, bupropion may be appropriate for that indication, but do not prescribe it expecting cognitive improvement. The evidence clearly shows it does not work for this purpose 1.